CTSU - IRB SUBMISSIONA Phase III Trial To Evaluate The Efficacy Of The Addition Of Inotuzumab Ozogamicin (A Conjugated Anti-Cd22 Monoclonal Antibody) To Frontline Therapy In Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL.
- Randhawa, Jasleen (PI)
- Abdelrahim, Maen (CoI)
- Bernicker, Eric H. (CoI)
- Chang, Jenny C. (CoI)
- Heyne, Kirk (CoI)
- Niravath, Polly A. (CoI)
- Singh, Monisha (CoI)
- Zhang, Jun (CoI)
- Patel, Tejal (Key Personnel)
Project: Non Profit